Back to ABBV
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Relapsing-Remitting Multiple Sclerosis
View Full LandscapeDrug Information
Target Indication
Relapsing-Remitting Multiple Sclerosis
Clinical Trial
NCT00390221Last updated: 11/15/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA7/1/2016
Zinbryta
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
